Press Releases

Press Releases

November 10, 2022
IRVING, Texas --(BUSINESS WIRE)--Nov. 10, 2022-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the Jefferies London Healthcare Conference , November
November 8, 2022
Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, Texas --(BUSINESS WIRE)--Nov. 8, 2022-- Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized
November 7, 2022
IRVING, Texas --(BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms.
October 10, 2022
IRVING, Texas --(BUSINESS WIRE)--Oct. 10, 2022-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time
September 7, 2022
Biote Method to be available in IMAC outpatient medical clinics IRVING, Texas --(BUSINESS WIRE)--Sep. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has
August 25, 2022
Company will resume trading under its existing symbols “BTMD” and “BTMDW” IRVING, Texas --(BUSINESS WIRE)--Aug. 25, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq
August 24, 2022
IRVING, Texas --(BUSINESS WIRE)--Aug. 24, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr.
August 9, 2022
Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance * Revised Dial -in Information for the Conference Call* IRVING, Texas --(BUSINESS WIRE)--Aug. 9, 2022-- Biote , a high growth, differentiated medical practice-building business
Displaying 1 - 10 of 25